Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.34 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.32 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.32 |
| ▸ | FLT3 | P36888 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25365358 | 1.00 | ESR1 (0.34) | ESR1ESR2KCNQ3KCNQ2FLT3 | |
| SCHEMBL24702322 | 0.80 | ESR1 (0.35) | ESR1ESR2KCNQ3KCNQ2FLT3 | |
| SCHEMBL23975685 | 0.78 | ESR1 (0.37) | ESR1ESR2KCNQ3KCNQ2PDE10A | |
| SCHEMBL25543154 | 0.78 | ESR1 (0.37) | ESR1ESR2TLR7 | |
| SCHEMBL14207964 | 0.78 | ESR1 (0.37) | ESR1ESR2KCNQ3KCNQ2PDE10A | |
| SCHEMBL26798301 | 0.75 | ALDH1A1 (0.33) | ESR1ESR2KCNQ3KCNQ2TLR7 | |
| SCHEMBL23179021 | 0.75 | ALDH1A1 (0.33) | ESR1ESR2KCNQ3KCNQ2TLR7 | |
| SCHEMBL26512216 | 0.74 | ESR1 (0.35) | ESR1ESR2KCNQ3KCNQ2PDE10A | |
| SCHEMBL24702302 | 0.74 | ESR1 (0.35) | ESR1ESR2PDE10A | |
| SCHEMBL16219338 | 0.74 | FLT3 (0.32) | ESR1ESR2KCNQ3KCNQ2FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018125-A1 | CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS | ERMIUM THERAPEUTICS (FR) | 2024-01-18 | — | — | US | disclosed |
| EP-4217353-A1 | CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS | Ermium Therapeutics (FR) | 2023-08-02 | — | — | EP | disclosed |
| WO-2022064075-A1 | CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS | ERMIUM THERAPEUTICS (FR) | 2022-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018125-A1 | CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS | CXCR4, CXCR1, CXCL12 | ESR1 1132/4885ESR2 353/4885KCNQ3 4532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.